Skip to main content
News Krawitz 02.2022
© Colourbox

News categories: Publication

AI-driven facial analysis improves diagnosis

Researchers at the University of Bonn use artificial intelligence (AI) to detect rare diseases even more accurately

Rare genetic diseases can sometimes be recognized through facial features, such as characteristically shaped brows, nose or cheeks. Researchers of the Cluster of Excellence ImmunoSensation2 have now trained software that uses portrait photos to better diagnose such diseases. The study has now been published in the journal "Nature Genetics".

Many sufferers of rare diseases endure an odyssey until the correct diagnosis is made. "The goal is to detect such diseases at an early stage and initiate appropriate therapy as soon as possible," says Prof. Dr. Peter Krawitz from the Institute for Genomic Statistics and Bioinformatics (IGSB) at the University Hospital Bonn. The researcher is a member of the Cluster of Excellence ImmunoSensation2 and the Transdisciplinary Research Area "Modelling" at the University of Bonn.

The majority of rare diseases are genetic. The underlying hereditary mutations often cause varying degrees of impairment in different areas of the body. In most cases, these hereditary changes are also expressed by characteristic facial features: for example, because eyebrows, the base of the nose or the cheeks are shaped in a distinctive way. However, this varies from disease to disease. Artificial intelligence (AI) uses these facial characteristics, calculates the similarities, and automatically links them to clinical symptoms and genetic data of patients. "The face provides us with a starting point for diagnosis," says Tzung-Chien Hsieh of Krawitz's team. "It is possible to calculate what the disease is with a high degree of accuracy."

The AI system "GestaltMatcher" described in the current publication is a continued development of "DeepGestalt", which the IGSB team trained with other institutions a few years ago. While DeepGestalt still required about ten non-related affected persons as a reference for training, its successor "GestaltMatcher" requires significantly fewer patients for feature matching. This is a great advantage in the group of very rare diseases, where only a few patients are reported worldwide. Furthermore, the new AI system also considers similarities with patients who have also not yet been diagnosed, and thus combinations of characteristics that have not yet been described. GestaltMatcher therefore also "recognizes" diseases that were previously unknown to it and suggests diagnoses based on this. "This means we can now classify previously unknown diseases, search for other cases and provide clues as to the molecular basis," says Krawitz.

The team used 17,560 patient photos, most of which came from digital health company FDNA, which the research team worked with developing the web service through which the AI can be used. Around 5,000 of the photos and patient data were contributed by the research team at the Institute of Human Genetics at the University of Bonn, along with nine other university sites in Germany and abroad. The researchers focused on disease patterns that were as diverse as possible. They were able to consider a total of 1,115 different rare diseases. "This wide variation in appearance trained the AI so well that we can now diagnose with relative confidence even with only two patients as our baseline at best, if that's possible," Krawitz says.

"We are very happy to finally have a phenotype analysis solution for the ultra-rare cases, which can help clinicians solve challenging cases, and researchers to progress rare disease understanding," says Aviram Bar-Haim of FDNA Inc. in Boston, USA. In Germany, too, the application in doctors' offices, for example, is not far off, adds Krawitz. Doctors can already use their smartphones to take a portrait photo of a patient and use AI to make differential diagnoses, he says. "GestaltMatcher helps the physician make an assessment and complements expert opinion."

Peter Krawitz and his team turned over the data they collected themselves to the non-profit Association for Genome Diagnostics (AGD), to provide researchers with access. "The GestaltMatcher Database (GMDB) will improve the comparability of algorithms and provide the basis for further development of artificial intelligence for rare diseases, including other medical image data such as X-rays or retinal images from ophthalmology," Krawitz says.


Participating institutions and funding

In addition to the Institute for Genomic Statistics and Bioinformatics and the Institute of Human Genetics of the University Hospital Bonn, the Charité-Universitätsmedizin Berlin, the universities of Greifswald, Tübingen, Düsseldorf, Lübeck, Heidelberg, the Technical University of Munich as well as universities from South Africa, France, the USA and Norway were involved. The study was mainly funded by the German Research Foundation (DFG).


Publication

Tzung-Chien Hsieh et al: GestaltMatcher: Overcoming the limits of rare disease matching using facial phenotypic descriptors, Nature Genetics, DOI: 10.1038/s41588-021-01010-x


Contact

Prof. Dr. med. Dipl. Phys. Peter Krawitz

Institute for Genomic Statistics and Bioinformatics (IGSB)

University Hospital Bonn

Phone: +49 228 287 14799

Email: pkrawitz@uni-bonn.de

Related news

News Icon

News categories: Publication

A fatal mix-up: how certain gut bacteria drive multiple sclerosis

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of multiple sclerosis, as researchers at the University of Basel, together with colleagues in Bonn, have shown in trials with mice. However, their results also open up opportunities for treatments that make use of the microbiome. The results have now been published in the journal Gut Microbes.
View entry
News Icon

News categories: Publication

New vulnerability of asthma immune cells discovered

Why do certain immune cells remain permanently active in allergic asthma – even in an environment that should actually damage them? A team from the University Hospital Bonn (UKB) and the University of Bonn has discovered that these cells only survive because they activate a special antioxidant protection mechanism. When this mechanism is blocked, allergic inflammation in mouse models decreases significantly. The results have now been published in the scientific journal Immunity.
View entry
The human P2X4 receptor

News categories: Publication

A starting point for the development of new pain and cancer drugs

The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry

Back to the news overview